Celltrion Confirms Neutralising Potency vs Emerging SARS-CoV-2 Variants With Anti-COVID-19 Monoclonal Antibody

 

• CT-P59 demonstrated neutralising capability against key emerging mutations, including SARS-CoV-2 variants first identified in New York (B.1.526), Nigeria (B.1.525) and India (B.1.617)1
• Evaluation of other emergent variants of concern (first identified in Brazil P.1)2 is ongoing; data expected in the coming months
• Celltrion is committed to assess the therapeutic neutralising antibodies against a wide array of emerging variants to end the pandemic

https://www.businesswire.com/news/home/20210517006051/en/Celltrion-Confirms-Neutralising-Potency-Against-Emerging-SARS-CoV-2-Variants-With-Anti-COVID-19-Monoclonal-Antibody-Treatment-regdanvimab-CT-P59